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M esenchymal stem cells may differentiate into angiogenic and osteoprogenitor cells. The effec-tiveness of autologous pluripotent mesenchymal cells for treating bone defects has not beeninvestigated in humans. We present a case series to evaluate the rationale of using nucleated cells
from autologous bone marrow aspirates in the treatment of severe bone defects that failed to respond to tra-
ditional treatments.
Ten adult patients (mean age, 49.6-years-old) with severe bone defects were included in this study. Lower
limb bone defects were ≥5 cm3 in size, and upper limb defects ≥2 cm.3 Before surgery, patients were tested for
antibodies to common pathogens. Treatment consisted of bone allogeneic scaffold enriched with bone mar-
row nucleated cells harvested from the iliac crest and concentrated using an FDA-approved device. Post-
surgery clinical and radiographic follow-up was performed at 1, 3, 6, and 12 months. To assess viability,
morphology, and immunophenotype, bone marrow nucleated cells were cultured in vitro, tested for sterility,
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Bone defects that do not respond to
conventional medical/surgical treat-
ments represent a major challenge for
orthopedic surgeons. Cell-based thera-
pies aim at regenerating damaged tissues
that fail to heal after traditional treat-
ment. In orthopedic surgery, platelet-
derived growth factors (PDGFs) and
bone morphogenetic proteins (BMPs)
have been used to stimulate bone regen-
eration in a variety of clinical condi-
tions, including long bone non-unions,
spinal fusion surgery, and repair of
symptomatic posterolateral lumbar
spine non-unions.1,2 While stem cells of
different origin (eg, bone marrow,
peripheral blood, skeletal muscle
myoblasts) have been widely investigat-
ed in other medical specialties, mainly
cardiology, cell therapy has been utilized
to a lesser degree in or thopedic
surgery.3-9
In small animals, bone marrow stem
cells favor healing or fractures and
repair of tendons.10,11 Bone marrow
mesenchymal stem cells (MSCs) are
multipotent cells that reside in the bone
marrow in proximity to hematopoietic
stem cell niches, and are involved in
bone marrow homeostasis and in regu-
lating the maturation of both
hematopoietic and non-hematopoietic
cells.12,13 The MSCs have the potential
to proliferate and differentiate into
osteoblasts, chondroblasts, odonto-
blasts, and adipocytes.14 Because they
can be easily obtained from bone mar-
row aspirates in adults, and either
directly implanted in vivo or expanded
in vitro before implantation, MSCs have
great potential for clinical applications.
Thus, when matrix and osteoprogeni-
tors are scarce–as in the case of large
bone defects–cell-based therapies might
provide novel treatment options.8
Bone healing requires implanted cells
to differentiate into osteoblasts, secrete
matrix constituents, and ultimately dif-
ferentiate into osteocytes. Differentia-
tion requires several genes to be turned
on (and off) in a growth- and differenti-
ation-specific manner. For instance, in
mice, Notch signaling inhibits osteoblast
differentiation through the Hes/Hey
proteins that reduce Runx2 transcrip-
tional activity.15 These studies suggest
that MSCs could be expanded in vitro
by activating the Notch pathway, where-
as in vivo differentiation and bone for-
mation would require suppressing this
pathway. In the same cell line, over-
expression of the dentin matrix protein
1 in MSCs induced their differentiation
into odontoblast-like cells.16 The
process requires the regulated activation
of transcription factors (eg, core bind-
ing factor 1), expression of BMP2 and
BMP4, genes associated with extracellu-
lar matrix (ECM) deposition (eg, alka-
line phosphatase, osteopontin,
osteonectin, osteocalcin), and late genes
like DMP2 and dentin sialoprotein.16
Although much experimental knowl-
edge exists in the literature, the clinical
application of adult MSCs for treating
large bone defects is still in its infancy.
12,17-22
Differentiation of stem cells into
bone tissue is influenced by environ-
mental factors, including the interaction
of cells with an adequate extracellular
scaffold, the supply of oxygen and
growth factors, and mechanical proper-
ties of the microenvironment.22-24 These
studies indicated that substantial num-
bers of cells and an adequate scaffold
were essential for bone formation. In
principle, cell-based therapies for bone
regeneration should include isolating,
expanding in vitro, and inducing the dif-
ferentiation of progenitor cells before
re-implantation within an adequate
ECM. However, there are numerous
ethical and legal considerations inherent
with these procedures.9,25-30 In this con-
text, utilizing sufficient numbers of
autologous MSCs during immediate
implantation is an attractive approach.
This approach would eliminate culture-
derived problems, including cell aging,
cell reprogramming, and contamina-
tion/infection by microbes and/or non-
autologous culture components.31
Recently, the U.S. Pharmacopeia, which
establishes written and physical stan-
dards for medicines, food ingredients,
dietary supplement products, and ingre-
dients addressed the safety aspects of
cell therapy by recommending simple
procedures whenever applicable.27
The current case series presents a
INTRODUCTION 
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and assayed for the possible replication of adventitious (contaminating) viruses.
In 9 of 10 patients, both clinical and radiographic healing of the bone defect along with bone graft integra-
tion were observed (mean time, 5.6 months); one patient failed to respond. No post-operative complications
were observed. Bone marrow nucleated cells were enriched 4.49-fold by a single concentration step, and
these enriched cells were free of microbial contamination. The immunophenotype of adherent cells was com-
patible with that of mesenchymal stem cells. We detected the replication of Epstein-Barr virus in 2/10 bone
marrow cell cultures tested. Hepatitis B virus, cytomegalovirus, parvovirus B19, and endogenous retrovirus
HERV-K replication were not detected. Overall, 470 to 1,150 million nucleated cells were grafted into each
patient. 
This case series, with a mean follow-up of almost 2 years, demonstrates that an allogeneic bone scaffold
enriched with concentrated autologous bone marrow cells obtained from the iliac crest provides orthopedic
surgeons a novel option for treating important bone defects that are unresponsive to traditional therapies.
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novel approach based on the use of
autologous MSCs and allogeneic bone
graft as a scaffold for treating large bone
defects that failed to respond to tradi-
tional medical and surgical therapies.
From November 2008 to September
2011, 10 patients (7 males [70%] and 3
females [30%]) suffering from severe
bone defects were recruited into the
study. Inclusion criteria comprised: 1)
bone defects and altered bone-consoli-
dations unresponsive to previous surgi-
cal treatments, 2) minimum defect size
≥5 cm3 (lower limb) or ≥2 cm3 (upper
limb), and 3) in the case of non-union
or delayed consolidation, a minimum of
2 months was required from the last
surgery. Exclusion criteria included: 1)
local or systemic infection, 2) radi-
ographic evidence of epiphyseal growth
cartilage, 3) severe soft tissue alter-
ations that could not allow proper bone
covering at the implantation site, 4)
pathologic fractures or neoplastic
lesions, 5) severe metabolic and autoim-
mune disease, 6) anti-neoplastic thera-
py, and 7) pregnancy.
Patients were treated at the Depart-
ment of Orthopaedic Surgery and Trau-
matology, University of Insubria,
Varese, Italy. Approval of the Hospital
Ethics Committee and the written,
informed consent of patients were
obtained for all patients. The mean age
of patients was 49.6-years-old (range,
17-84). Different pathologies were
treated: 6 cases of femur non-unions
(60%), 1 tibial shaft non-union (10%),
1 humerus non-union (10%), 1 very
severe bone loss secondary to complex
exposed leg fracture (10%), and 1 prox-
imal humerus cyst (10%) which
required 3 humeral shaft fractures to be
treated conservatively.  As shown in
Table I, patients were tested for serum
antibodies to common pathogens (Tre-
ponema pallidum, human immunodefi-
ciency virus (HIV), hepatitis B virus
(HBV), hepatitis C virus (HCV),
cytomegalovirus (CMV), Epstein-Barr
virus (EBV), and parvovirus B19) prior
to surgery.
Harvest and processing of bone
marrow cells.
In these studies, we utilized the
SmartPReP-2 Bone Marrow Aspirate
Concentrate System (Harvest Technolo-
gies GmbH, Munich, Germany)–a dedi-
cated, FDA-approved, CE-marked
device consisting of a centrifuge system
for producing autologous bone marrow
aspirate concentrate (BMAC).  Fresh
bone marrow aspirate (BMA; 60-120
ml.) was introduced in a disposable dual
chamber of the table-top centrifuge sys-
tem; the first chamber contained a
floating layer of a specific density. Dur-
ing centrifugation, red blood cells
(RBCs) were separated from nucleated
cells, platelets and plasma, then cellular
elements and plasma automatically
decanted into the second chamber and
concentrated by centrifugation. A por-
tion of plasma was removed, and cellu-
lar elements were re-suspended in
approximately 12 ml. of plasma. (The
concentration step was accomplished in
15 minutes.) The BMAC contained
unchanged proportions of myelocytes,
granulocytes, lymphocytes, monocytes,
proerythroblasts, and erythroblasts as
compared to the initial bone marrow
aspirate.32 Bone marrow aspirate was
obtained from the posterior iliac crest
using a 6 lumen Jamshidi type trocar
needle and 20-ml. syringes pre-flushed
with Na-heparin (1,000 units/ml.). The
trocar was initially directed at a 30°
angle to the horizontal plane, and paral-
lel to the plane of the crest. It was then
inserted 5 cm. toward the anterior cor-
tex. At least 60 ml. of BMA were
extracted while rotating and slowly
withdrawing the needle toward the cor-
tex. The BMA was then concentrated
using the SmartPReP-2 system in the
operating suite, and BMAC (≥10 ml)
was then transferred under sterile con-
ditions to the surgical field, together
with an appropriate amount of homolo-
gous bone graft obtained from the local
bone bank.
Surgical methods.
The surgical technique required
exposure of the bone defect, tissue
swabbing for microbiologic cultures,
debridement of the bony surface until
viable tissue was visible, and subsequent
grafting of allogeneic bone (Bone Bank,
Istituto Ortopedico Gaetano Pini,
Milan, Italy) enriched with BMAC.
Mechanical stability was thoroughly
evaluated and accounted for. At the end
of surgery, 2 ml. of BMA and approxi-
mately 0.5 ml of BMAC were submitted
to the Microbiology laboratory for the
following assessments: 1) pre- and post-
concentration cell counts, 2) sterility
tests, 3) culture of nucleated cells to
assess cell morphology, replication, and
differentiation, and 4) assessment of
virus-induced CPE and of adventitious
viruses.
Pre-operative serologic status of
patients.
Pre-operative serum specimens from
patients were tested for multiple
pathogens, in which antibodies to HIV,
HBV, HCV, CMV, EBV, and parvovirus
B19 were utilized in enzyme-linked
immunosorbent assays (ELISA; DiaSorin
S.p.A., Saluggia (Vercelli), Italy; Biotrin
International, Dublin, Ireland). Anti-
bodies to T. pallidum were assayed
against recombinant antigens (DiaSorin
S.p.A.).
Bone marrow cell cultures.
Two samples of bone marrow (pre-
and post-concentration) were obtained
in heparin tubes from each patient.
Blood cell counts were obtained using
routine analyzers (Sysmex Europe
GmbH, Norderstedt, Germany).
Nucleated cells were isolated by cen-
trifugation on two different Ficoll-
Histopaque gradients (1.077 and 1.199
g/ml.). Cell viability was evaluated by
trypan-blue exclusion. Cell suspensions
were plated in 75-cm2 tissue culture
flasks using Mesenchymal Stem Cell
Growth Medium (Lonza, Basel,
Switzerland) with added basic fibroblast
growth factor (bFGF; 5 ng/ml.) and
incubated at 37°C in air with 5% CO2.
Stromal cells adhered to plastic within
48 hours after plating, with cell replica-
tion initiating after adhesion. Upon
reaching confluency in 5-7 days, adher-
ent cells were harvested using trypsin-
EDTA and re-plated for subsequent in
vitro passage. We collected supernatant
from each culture at different times,
clarified them by low-speed centrifuga-
tion, aliquoted the supernatants, and
froze them at –70°C in liquid nitrogen
before processing.
Cell cultures were observed at 3-day
intervals using a phase-contrast micro-
scope with a digital camera to evaluate
cell morphology and the possible devel-
opment of CPE. Images were acquired
with a 10X, 20X, and 40X objective and
recorded using a computerized image
analysis system (Image DB, Amplimed-
ical, Mira, Italy).
Sterility tests and Mycoplasma
detection.
Aliquots of BMA, BMAC, and bone
marrow cells that were cultured for 2-4
weeks were inoculated into both aero-
MATERIALS AND METHODS 
- 4 -
#410 Vulcano#Final
Treatment of Severe Post-traumatic Bone Defects With Autologous Stem Cells Loaded on Allogeneic Scaffolds
VULCANO/MURENA/CHERUBINO/FALVO/ROSSI/BAJ/TONIOLO
bic and anaerobic blood culture vials
(BACTEC™ Plus Aerobic/F medium
and Plus Anaerobic/F Vials; Becton
Dickinson and Company, Franklin
Lakes, New Jersey) and incubated for
14 days. Cell culture supernatants were
also tested for Mycoplasma spp. using a
commercial kit (MycoAlert® Mycoplas-
ma Detection Kit, Lonza. Rockland,
Maine), which employs measurements
of enzymatic ATP-conversion combined
with luminescence. The test can detect
a wide range of Mycoplasma species,
including the more common M. fermen-
tans, M. hyorhinis, M. arginini, M. orale,
and M. salivarium
Detection of adventitious viruses
in cultured bone marrow cells.
At the end of the 4-week culture
period, cell cultures were tested for
adventitious (contaminating) viruses by
polymerase chain reaction (PCR). The
DNA was extracted from cell pellets
(each consisting of 106 cells) using
QIAamp DNA Blood Midi Kit (QIA-
GEN GmbH, Hilden, Germany); the
QIAamp DNA Mini Kit (QIAGEN
GmbH) was used for supernatants. The
RNA was extracted from supernatants
using the QIamp Viral RNA Mini Kit
(QIAGEN GmbH). Both DNA and
RNA were eluted in 50 μL of buffer
AE, and RNA was extracted from cul-
tured cells using the acid guanidinium
thiocyanate and phenol chloroform
method (TRIzol,® Invitrogen, Carlsbad,
California). Samples were mixed with 2
volumes of RNAzol and extracted with
200 µl chloroform. The RNA-contain-
ing aqueous phase was then precipitated
with 500 μl isopropanol, and the cen-
trifuged RNA pellet was washed with
75% ethanol and resuspended in 50 μl
ster ile water. Viral genomes were
detected using amplification methods
specific to HBV, CMV, EBV, herpes sim-
plex virus-1 and -2 (HSV-1 and -2),
parvovirus B19  (diagnostic kits from
QIAGEN and QIAGEN-artus GmbH,
Hilden, Germany). Viral RNA was
retro-transcribed with the SuperScript®
VILO™ cDNA synthesis kit (Invitrogen)
and random hexamer primers. The
cDNA product was then amplified using
specific methods to detect HCV and
HIV (QIAGEN-artus GmbH), as well as
in-house test assays for the endogenous
retrovirus K.33
Characterization of cultured bone
marrow cells.
The surface expression of differentia-
tion markers was evaluated by flow
cytometry (FACSCalibur,™ Becton
Dickinson Biosciences, Franklin Lakes,
New Jersey) and immunofluorescence
assays. Mouse-derived monoclonal anti-
bodies were used to detect CD105,
CD73, CD90 (expected expression by
MSCs), CD45, CD34, and CD14
(expected lack of expression by MSCs)
in our assays. Cultured adherent cells
were washed with PBS, detached by
scraping, and counted. Cell suspensions
(approximately 106/ml. in FACS buffer)
were dispensed in sterile tubes (0.3
ml./tube) and incubated on ice with
antibodies directed against different
markers; FITC-labeled goat anti-mouse
was used as the secondary antibody.
Two negative controls were stained
with FITC-conjugated antibody:
unstained cells and cells incubated with
a non-relevant mAb (anti-HIV p24).
Patient follow-up.
According to the routine protocol
used at our Department of Trauma and
Orthopaedic Surgery, each patient was
evaluated clinically and radiographically
(2 plane x-rays) at five pre-determined
time points: 1) pre-operative, 2) 1
month post-operative, 3) 3 months
post-operative, 4) 6 months post-opera-
tive, 5) 12 months post-operative. The
patients’ adverse events (AEs) that
occurred while on study were recorded
and reported, and results analyzed using
observational statistics.
Serologic evaluation before
surgery.
As shown in Table I, no positive reac-
tions against T. pallidum, HIV, and HCV
were detected. Anti-HBc antibody was
found in 5 of 10 patients (50%), but
none was HBsAg-positive. Antibody
IgG to parvovirus B19 was detected in 6
of 8 patients (75%), and IgG against
EBV and CMV was present in all
patients (100%). Note that these data
corroborated the possible risk for sur-
geons by accidental infections by HBV,
EBV, CMV, and parvovirus B19.
Ability of the SmartPReP-2 to
concentrate nucleated cells in
bone marrow aspirates.
As shown in Table II, cell counts per-
formed before and after the concentra-
tion step showed that the procedure
strongly reduced RBC numbers, and
concentrated nucleated cells by mean
4.49 fold. Thus, the concentration step
allowed each patient to receive cell sus-
pensions containing 470-1,000 x106
nucleated cells plus 2-10 x109 platelets. 
Cell culture of bone marrow
aspirates: sterility tests and
phenotypic characterization of
adherent cells.
Nucleated cells from BMAs were
cultured for 4 weeks. Two days after
plating, a mixture of fibroblast-like and
hemispherical adherent cells began
growing and forming distinct colonies
that progressively transformed into
monolayers of adherent fibroblast-like
cells with rare hemispherical adherent
cells (Figs. 1a-1d).
Sterility tests performed on cultures
incubated for 4 weeks detected no bac-
ter ial or fungal contamination;
Mycoplasma contamination was also
absent (Table III). Cell viability was 93-
99%. Cytofluorimetry and immunoflu-
orescence assays showed that adherent
bone marrow cells from all patients
were negative for the CD45 hematopoi-
etic marker, negative for CD34
endothelial marker, and substantially
negative for the CD14 monocyte mark-
er. Cultured cells from all patients
expressed one or more of the surface
markers CD73, CD90, and CD105.
The antigen-profile results are in agree-
ment with the criteria of the Interna-
tional Society for Cellular Therapy that
define multipotent mesenchymal stro-
mal cells. 34 Thus, considerable num-
bers of mesenchymal stromal cells were
present in all of the patients’ concen-
trated BMAs.
Detection of adventitious viruses
in bone marrow cultures.
Adventitious viruses were evaluated
by observing the development of
cytopathogenic effect (CPE) in cell cul-
tures and by amplification of viral
genomes (Table IV). After 2-4 weeks of
incubation, 2 of 10 (20%) bone marrow
cultures developed CPE in fibroblast-
like cells that were characterized by
multiple cytoplasmic vacuoles and cell
fusion (Fig. 1e and 1f). Cells from both
patients continued to grow, but showed
reduced viability (88-93%). These cul-
tures were positive for EBV (assessed by
PCR), and cultures from Patient PM
contained 1,600 genome copies/105
cells, whereas those from Patient PA
had only 10 genome copies/105 cells.
While the latter value is normal for an
EBV-positive individual, the prior indi-
RESULTS
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Table I. Serological evaluation of patients before surgery.
Patient Age Gen-
der
Trepone-
ma palli-
dum
HIV HCV HBV
Parvovi-
rus
B19
EBV CMV
Total Ig
To-
tal 
Ig
IgG HB-
sAg
Anti-
HBc
IgG IgM IgG 
VCA
IgG
EBNA
IgM
VCA IgG IgM
01ZL 38 M - - - - - ND ND + + - + -
02AG 35 M - - - - + + - + + - + -
03PM 71 M - - - - + + - + + - + -
04FG 47 M - - - - - + - + + - + -
05TD 17 M - - - - - + - + + - + -
06GA 52 F - - - - - + - +(weak) + - + -
07MLD 84 F - - - - + + - + + - + -
08PA 50 M - - - - - - - + + - + -
09DA 59 M - - - - + ND ND + + - + -
10PG 43 F - - - - + - - + + - + -
No. Positive / No. 
tested 0/10 0/10 0/10 0/10 5/10 6/8 0/8 10/10 10/10 0/10 10/10 0/10
Table II. Bone marrow aspirates from patients. Cell counts before and after the concentration 
step in the SmartPReP-2 platform.
RBC  (x106/µl) Nucleated Cells (x103/µl) PLT (x103/µl)
Patient
Pre- Post- Concen-
tration 
factor
Pre- Post- Concen-
tration 
factor
Pre- Post- Concen-
tration 
factorconcentration concentration concentration
01ZL 4,50 2,10 0,47 15,63 68,20 4,36 159,00 581,00 3,65
02AG 4,42 1,95 0,44 20,11 64,06 3,19 76,00 303,00 3,99
03PM 4,23 2,53 0,60 14,97 74,12 4,95 111,00 496,00 4,47
04FG 4,59 3,41  0,74 30,50 115,00 3,77 131,00 481,00 3,67
05TD 4,02 1,85 0,46 15,70 63,99 4,08 143,00 509,00 3,56
06GA 3,53 1,46 0,41 15,14 68,58 4,53 115,00 436,00 3,79
07MLD 3,13 0,96 0,31 15,48 49,21 3,18 128,00 290,00 2,27
08PA 3,80 2,21 0,58 8,58 53,50 6,24 167,00 691,00 4,14
09DA 3,90 1,70 0,44 9,10 54,20 5,96 178,00 702,00 3,94
10PG 4,35 1,91 0,44 16,54 76,71 4,64 137,000 523,000 3,82
Mean
Standard
deviation
0,49 4,49 3,73
0,12 1,03 0,58
RBC :red blood cells; PLT: platelets
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cates that EBV replicated in Patient
PM’s cells in vitro. Given the oncogenic
potential of EBV, cell-based therapies
utilizing bone marrow cells that had
been expanded in vitro from this indi-
vidual might involve significant biologic
risk from EBV. Notably, this case sup-
ports the indications of the U.S. Phar-
macopeia that recently mandated
virology controls for cells expanded in
culture that are intended for therapeutic
use in humans.27 Although most patients
were seropositive for CMV and par-
vovirus B19, these viruses did not reac-
tivate in cultured bone marrow cells,
and there was no evidence of replication
of the endogenous retrovirus HERV-K.
Clinical outcomes.
The clinical data, size of the bone
defects, and number of implanted cells
are summarized in Table V. The mean
volume of bone defects, evaluated with
standard 2 plane radiographs, was 52.9
cm3 (range, 33-85 cm3).7,26 Unfortu-
nately, the precision of this x-ray imag-
ing method was only ± 30%.35 The
mean number of previous surgical treat-
ments was 3.3 (range, 1-15), with a
mean duration of 11.2 months (range,
4-68). In two patients (20%) who pre-
sented with non-union defects, the rup-
ture of previously positioned plates was
observed. The mean follow-up time
was 23.8 months (range, 14-36). Dur-
ing surgery, four patients (40%) under-
went plate substitution to treat either
plate failure or inadequate size.
At mean 5.6 months after surgical
intervention (range, 2-12), 9 of 10
patients (90%) had full osteointegration
of the bone graft and complete healing
of bone defects, as observed on radi-
ographs (Fig. 2-Fig. 4). In one (10%),
neither clinical nor radiographic healing
was achieved. The patient presented
with an open leg fracture with signifi-
cant loss of skin and bone, secondary to
a penetrating trauma. Shortly after
damage-control surgery consisting of
irrigation and debridement, and frac-
ture stabilization with an external fixa-
tor, the patient developed local
infection by Pseudomonas aeruginosa,
and was treated accordingly. After
repeated negative microbiologic tests,
the patient underwent plastic surgery to
cover the soft-tissue defect. At four
months post surgery, and in the absence
of laboratory and clinical signs of infec-
tion, the patient underwent allogeneic
bone graft and BMAC infusion. One
month after surgery, a pus-secreting fis-
tula appeared at the affected site,
whichwe later confirmed as a reactiva-
tion of the Pseudomonas aeruginosa
infection. Nevertheless, four months
postoperatively, radiographic examina-
tion documented integration of approx-
imately 50% of the bone graft at the
proximal portion of the bone defect.
The graft, however, was insufficient to
guarantee mechanical stability. 
In 2007, Giannoudis et al. described
the key to bone restoration and regen-
eration in terms of the “diamond con-
cept.” 23 They provided evidence to
support four parameters that positively
influenced bone formation and over-
came impaired healing of bone frac-
tures: 1) utilization of growth factors,
2) incorporation of scaffolds, 3) mes-
enchymal stem cell use, and 4) stable
mechanics.
Experimental and clinical studies
have shown that autologous  mononu-
clear cells from bone marrow used in
combination with biocompatible scaf-
folds support osteogenesis in animals
Figures 1A and 1B. Cultures of adherent bone marrow cells 5 days post-plating. In both cases, most
cells show fibroblast-like morphology (case 04AG, A; case 10BA, B. Original magnification 100x).
1C and 1D. Cultures of adherent bone marrow cells 12 days post-plating. In both cases, mixtures of
fibroblast-like and hemispherical adherent cells are present (case 01ZL, C; case 07MLD, D. Original
magnification 200x).
1E and 1F. Cultures of adherent bone marrow cells 12 days post-plating. Cytopathic effect associated
to Epstein-Barr virus infection is see as multiple cytoplasmic vacuoles in fibroblast-like cells (case
03PM. Original magnification: 200x, E; 400x, F ).
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Table III. Sterility tests and phenotypic characterization of adherent cells cultured from bone 
marrow aspirates of patients.
Pa-
tient
Ste-
rility
Myco-
plasma 
detec-
tion2
Cell 
vi-
ability 
(%)3
Adhe-
sion to 
plas-
tic4
Cell morphology4
Surface markers of adherent cells5
CD 
34
CD 
45
CD 
14
CD
73
CD
90
CD 
105
01ZL + - 97 + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - + + ND
02AG + - 97 + 4,*'-.'%&! - ND - + + +
03PM + - 92 + 4,*'-.'%&! - - - + + +
04FG + - 98 + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - ND + ND
05TD + - 97 + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - + + +
06GA + - 95 + 4,*'-.'%&! - - - + + +
07MLD + - 98 + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - + + +
08PA + - 95 + 4,*'-.'%&! - - - + + +
09DA + - 98 + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - + + +
10PG + - 96w + 
4,*'-.'%&!

$!(%-+$!,%' $!,!).!''-
- - - + + +
**-%.%0!	*!-.! 
	
 
	 
	
 	 
	
 	
)*. !.!.! 
 .!,%'%.3.!-.-*, %)#.*,%.!,%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Table IV. Detection of viral agents in cultures of bone marrow aspirates from each patient by 
observing the development of cytopathic effect and using gene amplification methods.
Patient Cytopathic effect in cultured cells1
Parvovirus 
B19
Amplification of viral genomes2
EBV CMV HSV-1/2 HBV HERV-K
01ZL - - - - - - -
02AG - - - - - - -
03PM Cytoplasmic vacuolation
- 1,600 (genome 
equivalents/105 cells) - - - -
04FG - - - - - - -
05TD - - - - - - -
06GA - - - - - - -
07MLD - ND ND ND ND ND ND
08PA Weak - 10 (genome equiva-lents/105 cells) - - - -
09DA - - - - - - -
10PG - - - - - - -
No. Positive/
No. Tested
2/10 0/9 2/9 0/9 0/9 0/9 0/9
ND not detected
1. Evaluation of cytopathic effect through serial examination by phase-contrast microscopy.
2. 
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Our study had three major inherent
limitations: 1) the relatively small num-
ber of cases, 2) lack of a control group,
and 3) heterogeneity of clinical diag-
noses. Despite clinical and radiographic
success in most cases, these data may
not necessarily yield comparable results
in patients with different diagnoses that
lead to bone defects or those with larg-
er defects. However, these data provide
the rationale for a larger, prospective
randomized controlled trial (RCT) of
autologous stem cells loaded on allo-
geneic scaffolds.
Despite symptomatic improvement
and significant bone formation in 9 of
10 patients (90%), our treatment failed
to cure all of the bone defects. In this
limited series, however, our protocol
using autologous BMAC in combination
with allogeneic bone grafts was safe and
efficacious in both the short and long-
term, without significant impact on
total operating time, thus benefitting
and in humans, respectively.8-9, 36-40 Dif-
ferentiation of osteoprogenitor cells is
significantly dependent on the microen-
vironment, thus facilitating the use of
BMAC as a viable option for therapeutic
angiogenesis and bone regeneration.41-44
The present study describes the com-
plete healing of bone defects that are
refractory to traditional surgery within
3-12 months following treatment with
BMAC in 9 of 10 patients (90%). The
one failure was observed in a patient
with a complex, severe leg injury, who
was accrued on study as an extreme
measure to avoid limb amputation.
While the cases investigated in our case
series were heterogeneous and clinically
complex, all had been unresponsive to
conventional medical/surgical interven-
tion. Hence, the complete healing that we
observed in 9 patients was encouraging.
Table V. Characteristics of patients.
Patient
Age at 
sur-
gery 
(years)
Sex Affected site Diagno-
sis
No. of 
previous 
surger-
ies
Size of
bone 
defect
(cm3)
No. of implant-
ed bone marrow 
nucleated cells 
(x106)
Clinical and 
radiograph-
ic healing 
(months)
01ZL 38 M Proximal metaphy-
seal femur
Non-union 2 47 680 12
02AG 35 M Distal metaphyseal 
femur
Non-union 15 45 640 6
03PM 71 M Mid-humerus shaft Non-union 0 49 740 3
04FG 47 M Femur proximal shaft Non-union 6 33 1,150 9
05TD 17 M Meta-diaphyseal 
proximal humerus
Bone cyst 1 85 640 3
06GA 52 F Distal metaphyseal 
femur Non-union 1 33 680 3
07MLD 84 F Distal metaphyseal 
femur Non-union 1 59 490 6
08PA 50 M Mid 1/3 tibia shaft
Complex 
open leg 
fracture
4 74 530 failure
09DA 59 M Distal metaphyseal 
femur
Non-union 1 53 540 4
10PG 43 F Mid 1/3 tibia shaft Non-union 2 51 570 4
Figure 2. An 84 year-old female, with distal femur fracture treated with a plate in May 2008. Failure of
the plate occurred in May 2009, with evident non-union. In May 2009, the patient underwent surgery,
including removal of hardware, implantation of an intramedullary retrograde nail, and BMAC plus allo-
geneic bone grafting. The figure illustrates bone healing at 6 months.
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clinical outcomes and resource utiliza-
tion. Bone marrow samples (before and
after concentration) remained consis-
tently sterile, and the cost of the proce-
dure was relatively inexpensive
compared to alternative methods and
more expensive drugs (eg, bone mor-
phogenetic proteins) that are used to
treat large bone defects. The BMAC Kit
was purchased by our Institution at a
significantly lower cost than the OP1
Bone Morphogenetic Protein (Stryker,
Mahwah, New Jersey).
In addition, there was no morbidity
associated with autologous bone graft
transplantation (eg, infections, seromas,
hematomas, herniation of abdominal
contents, vascular injuries, neurologic
injuries, iliac wing fractures), and no
significant side effects were observed. 46
Further advantages of the one-stage iso-
lation procedure in comparison to the
ex-vivo expansion of autologous cells
from bone marrow are the reduced cost
and the absence of infections attribut-
able to the complex procedures
required for cellular expansion. 8
Analysis of cell differentiation mark-
ers and virologic studies showed that
considerable numbers of mesenchymal
stem cells were readily obtainable from
bone marrow aspirates of adult patients,
and that virus reactivation was rarely
detected in bone marrow cells. Another
major advantage was the elevated
platelet concentration (approximately
373%) that we reported in this study.
When activated, platelets release gran-
ules that are rich in tissue (including
bone) growth factors, cytokines and
chemokines, such as platelet-derived
growth factor (PDGF-αα, ββ and αβ
isomers), transforming growth factor
(TGF-β, β1 and β2 isomers), platelet
factor 4 (PF4), interleukin-1 (IL-1),
platelet-derived angiogenesis factor
(PDAF), VEGF, epidermal growth fac-
tor (EGF), platelet-derived endothelial
growth factor (PDEGF), epithelial cell
growth factor (ECGF), insulin-like
growth factor (IGF), osteocalcin,
osteonectin, fibrinogen, vitronectin,
fibronectin, and thrombospondin. 47-53
Adult mesenchymal stem cells,
osteoblasts, fibroblasts, endothelial cells
and epidermal cells respond to the
abovementioned proteins in multiple
pathways, and promote tissue/bone for-
mation. 51,54
We presented a new technique to
overcome impaired bone healing in
patients who are affected by large bone
defects that are unresponsive to tradi-
tional therapies. To further extend our
promising results, we encourage investi-
gators to conduct multicenter, prospec-
tive, RCTs to evaluate and understand
better the efficacy of BMAC grafts in
treating complex bone defects. Based
on our preliminary data, the procedure
might well provide clinical outcomes
that are comparable to those of current
autologous bone graft transplantation,
albeit with significantly less treatment-
related morbidity.
Overall, BMAC supplemented with
allogeneic bone delivered platelet-
derived growth factors locally and mes-
enchymal stem cells, and mechanical
stability was conferred by the bone scaf-
Figure 4. A 71 year-old male, with mid-humeral shaft fracture treated conservatively, developing non-
union, who was treated with plate and BMAC plus allogeneic bone grafting. The figure illustrates bone
healing at 3 months.
Figure 3. A 17 year-old male with a proximal humerus bone cyst that caused 3 fractures, who was treat-
ed with BMAC plus allogeneic bone grafting. The figure illustrates bone healing at 6 months.
CONCLUSIONS
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fold–the elements that meet the “dia-
mond concept” of Giannoudis et al. 23
Given the safety, efficacy, cost-effective-
ness, and simplicity, we encourage the
use of allogeneic bone grafts enriched
with autologous concentrated bone
marrow cells obtained from the iliac
crest for treating large bone defects that
are unresponsive to traditional thera-
pies. Moreover, future investigation
should assess how the overall “organis-
mal state” of the patient influences those
mechanisms that regulate the produc-
tion and function of bone marrow pre-
cursor stem cells. 55
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